Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Dual Phase 1/2, Investigator Initiated Study to Determine the Maximum Tolerated Dose, Safety, and Efficacy of 186Rhenium Nanoliposomes (186RNL) in Recurrent Glioma (CTRC 12-02)

Next Previous
Trial Profile

A Dual Phase 1/2, Investigator Initiated Study to Determine the Maximum Tolerated Dose, Safety, and Efficacy of 186Rhenium Nanoliposomes (186RNL) in Recurrent Glioma (CTRC 12-02)

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 09 Feb 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rhenium (186Re) obisbemeda (Primary)
  • Indications Astrocytoma; Diffuse intrinsic pontine glioma; Ependymoma; Glioblastoma; Glioma
  • Focus Adverse reactions; First in man; Registrational; Therapeutic Use
  • Acronyms ReSPECT; ReSPECT-GBM; ReSPECT-TM
  • Sponsors Plus Therapeutics

Most Recent Events

  • 22 Jan 2026 According to the Plus Therapeutics Media Release, company plans to complete enrollment in this ReSPECT-GBM Phase 2 trial for glioblastoma and conduct an end of phase meeting with the FDA to align on pivotal trial design, with data expected in Q4 2026.
  • 04 Dec 2025 According to the Plus Therapeutics Media Release, data from this study were presented at the World Federation of Neuro-Oncology Societies/Society for Neuro-Oncology (WFNOS/SNO) Annual Meeting, November 19-23, 2025 in Honolulu, Hawaii.
  • 04 Dec 2025 According to the Plus Therapeutics Media Release, ongoing Phase 2 study has enrolled 24 of planned 34 patients as of data cutoff.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top